Overview: Immunotyping TestIntroduction: The Immunotyping Test identifies abnormal immunoglobulins to diagnose multiple myeloma, causing bone pain or fatigue. Aligned with 2023 NCCN guidelines, it uses immunoassay for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected multiple myeloma or related plasma cell disorders.
Other Names: Immunoglobulin Typing Test, Myeloma Immunotyping Assay.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Immunotyping began in the 1970s with myeloma research. Immunoassay-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Identifies abnormal immunoglobulins to diagnose multiple myeloma, guides treatment, and evaluates patients with bone pain or fatigue.
Test Parameters: 1. Immunoglobulin Typing
Pretest Condition: No fasting required. Collect serum, plasma, urine, or saliva. Report history of bone pain, fatigue, or renal issues.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL), Urine (24-hour collection, 50-100 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document bone pain, fatigue, renal issues, or family history of multiple myeloma. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, myeloma implications, and risks of sample collection.
Procedural Considerations: Uses immunoassay to identify immunoglobulin profiles in serum, plasma, urine, or saliva. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for myeloma diagnosis.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. Insufficient sample volume may reduce accuracy.
Clinical Significance: Abnormal immunoglobulin profiles (e.g., monoclonal gammopathy) confirm multiple myeloma, guiding chemotherapy or transplant. Normal profiles may require further testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: Kappa/Lambda IHC, serum protein electrophoresis, or bone marrow biopsy to confirm multiple myeloma diagnosis.
Test Limitations: Not specific to multiple myeloma; other plasma cell disorders may show abnormal immunoglobulins. Clinical correlation is needed.
References: NCCN Multiple Myeloma Guidelines, 2023; Blood, Kyle RA, 2022.
